Hovione, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).
JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.
“We are excited to partner with Hovione and today’s agreement further strengthens JIXING’s ophthalmology pipeline beyond its current focus on presbyopia and dry eye disease,” said Peter Fong, PhD, board executive director, JIXING. “In addition, this agreement marks a significant step for the company as it highlights its development from a China focused, late clinical-stage biotech to an innovation pioneer with full life cycle development capabilities to reach customers and patients globally.”
“We are extremely pleased to enter into this partnership with JIXING and help the company build upon its existing ophthalmology pipeline while further enhancing Hovione’s leadership position in spray dried dispersions” said Marco Gil, VP Sales at Hovione adding “Our highly experienced and committed teams can support pharma and biotech companies worldwide on their path to clinical success and commercialization, offering the best scale-up science, extensive manufacturing capacity and an excellent approval track record.”
This Global License Agreement is aligned with Hovione’s strategy to offer integrated product solutions for drug delivery that co-create value with its partners and enable the development of innovative medicines that maximize patient benefit.
Destum Partners acted as business development and licensing transaction advisor to Hovione.